Pharmesis International Ltd
SGX:BFK
Pharmesis International Ltd
Inventory
Pharmesis International Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmesis International Ltd
SGX:BFK
|
Inventory
¥14.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Inventory
¥653.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Inventory
¥2.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Inventory
¥5.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Inventory
¥4.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Inventory
¥162.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Pharmesis International Ltd
Glance View
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
See Also
What is Pharmesis International Ltd's Inventory?
Inventory
14.2m
CNY
Based on the financial report for Dec 31, 2024, Pharmesis International Ltd's Inventory amounts to 14.2m CNY.
What is Pharmesis International Ltd's Inventory growth rate?
Inventory CAGR 10Y
10%
Over the last year, the Inventory growth was -8%. The average annual Inventory growth rates for Pharmesis International Ltd have been 17% over the past three years , 16% over the past five years , and 10% over the past ten years .
